Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Licensing and collaboration revenue	$ 2,664	$ 1,586
Operating expenses:
Research and development	13,924	10,165
General and administrative	9,593	4,596
Total operating expenses	23,517	14,761
Loss from operations	(20,853)	(13,175)
Other income (expense):
Change in fair value of equity securities	(88)	0
Change in fair value of the MSKCC success payments liability	1,596	(686)
Other income - net	257	16
Total other income (expense)	1,765	16
Net loss	(19,088)	(13,159)
Net unrealized loss on available-for-sale marketable securities, net of tax	(954)
Net comprehensive loss	$ (20,042)	$ (13,159)
Net loss per share, basic and diluted	$ (0.32)	$ (1.39)
Weighted-average common shares outstanding, basic and diluted	60,546,170	9,499,448